Are you sure you'd like to remove this alert? You will no longer receive email updates about this topic.
In this edition of Device Week, find out which were the most interesting startups showcased at AdvaMed’s annual Medtech Conference, held at the end of September. Additionally, the last week has seen a surge in acquisition activity – which were the more notable deals that were cut?
On this week's podcast, we highlighted progress by several startups in the molecular diagnostics space, and discussed growing scrutiny in the cardiology community of Boston Scientific's Watchman stroke device.
On this week’s podcast, we discuss big announcements from US FDA on digital health policy and an upcoming device-center reorganization, as well as the recent resignation of Tom Price as health secretary.
In this edition of Device Week, find out more about the increasing body of research into social media’s role in health care and what makes acute heart failure therapy specialist Magenta Medical a particularly interesting investment bet.
Discover upcoming tweaks to the agency’s facility inspection approach on this week's Medtech Insight podcast.
On this week's podcast, we discuss Medtech Insight's August analysis of global device approval trends.
US FDA recently exempted hundreds of device types from 510(k) submissions under a 21st Century Cures Act mandate. On this week's podcast, we discuss Medtech Insight's exclusive analysis of the impact of the exemptions on companies and FDA.
In this edition of Device Week, Medtech Insight’s Marion Webb and Tina Tan look more closely at the drivers that are accelerating the move away from centralized lab testing towards point-of-care settings like retail pharmacies, and highlight the challenges that still need to be addressed. They also delve into the ophthalmic space and look at what ocular drug delivery innovations are being developed to help fuel the fast growing ophthalmic drug market.
On this week's podcast, Medtech Insight's David Filmore and Ferdous Al-Faruque discuss the recently enacted FDA Reauthorization Act. It comes with higher industry fees, but also a host of US FDA commitments and reforms. The legislation was broadly supported by lawmakers and industry alike, but President Trump? Not so much.
In this week's Device Week podcast, we look at recent mergers and acquisitions. While the year started out slow, July was the busiest month for medtech M&A deals. At this rate the industry is set to break last year's deal count. We go in-depth into some of the major deals, and more.
All set! This article has been sent to firstname.lastname@example.org.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
Please Note: Only individuals with an active subscription will be able to access the full article. All other readers will be directed to the abstract and would need to subscribe.